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Abstract
Introduction: With the exception of the recent accelerated approval of aducanumab,
in over 26 years of research and development (R&D) investment in Alzheimer’s disease
(AD), only five novel drugs—all for symptomatic treatment only—have reached FDA
approval. Here, we estimate the costs of AD drug development during this period in
the private sector.
Methods: To estimate private R&D funding, we collected information on AD clinical
trials (n = 1099; phases 1–4) conducted between January 1, 1995 and June 21, 2021
from various databases. Costs were derived using previously published methodologies
and adjusted for inflation.
Results: Since 1995, cumulative private expenditures on clinical stage AD R&D were
estimated at $42.5 billion, with the greatest costs (57%; $24,065 million) incurred

Funding information
Data collection, analysis and the development
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during phase 3; approximately 184,000 participants were registered or are currently
enrolled in clinical trials.
Discussion: Measures to reduce expenditures while moving toward disease-modifying
therapies that alleviate the rising burden of AD require continued investment from
industry, government, and academia.
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1

BACKGROUND

than slowing disease progression or mitigating the underlying biological processes. This is the case in Alzheimer’s disease (AD), which

1.1
The high risk of drug development for
Alzheimer’s disease

remains one of the most difficult therapeutic areas for drug development and has a near 100% failure rate.2 Between 1995 and 2021, 878
drugs across all therapeutic areas have been approved by the US Food

Drug development and approval of effective and safe therapies that

and Drug Administration (FDA); only six of these drugs are indicated

alter the clinical course of neurodegenerative diseases (NDD) have

for AD (four cholinesterase inhibitors [ChEIs], memantine, and adu-

been especially challenging.1 Although there have been some suc-

canumab).

cesses, and with the exception of the recent accelerated approval of

Because of the high risk and lack of commercial success associated

aducanumab, the drugs approved for central nervous system (CNS) dis-

with CNS drug development, many pharmaceutical companies have

eases are largely those that effectively treat disease symptoms rather

drastically curtailed their investments in CNS diseases over the past

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 Biogen. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.
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20 years.3–5 Such measures likely reflect concerns regarding the limited availability of target engagement biomarkers, complex clinical trial

RESEARCH IN CONTEXT

designs, imprecise clinical measures, heterogeneous symptoms, limited
ability to affect the underlying causes of CNS diseases, and the lack
of predictive animal models

6,7 —all

1. Systematic review: The authors used multiple sources of
information to determine the research and development

of which contribute to high risk

costs in Alzheimer’s disease (AD) from 1995 to present.

with uncertain future revenues. AD drug development is the canonical example of this predicament. AD drug trials cost more per patient

2. Interpretation: Our findings highlight the cumulative
expense of conducting clinical trials in AD over the past

than trials in any other therapeutic area, with 50% to 70% of the cost
devoted just to patient

screening.8

quarter century ($42.5 billion), with the greatest costs

Recruiting for AD trials is diffi-

incurred in late-stage drug development, and reveal the

cult, and participant attrition is high since the trials are often longer

shift from research aimed at amyloid targets to that aimed

than trials in other therapeutic areas—especially for trials attempting

at more diverse disease targets.

to demonstrate disease modification and those focusing on secondary
prevention.

3. Future directions: AD is a pressing public health challenge, and new therapies are needed. The cost of AD
drug development is high, and failures are common. Bet-

1.2
AD

ter means of reducing and distributing costs, sharing risks,

Development of symptomatic therapies for

and improving development success are needed.

It has been more than 28 years since the first drug to treat AD, tacrine,
was approved in the US in 1993. The ChEIs tacrine, donepezil, rivastigmine, and galantamine were approved in 1993, 1996, 2000, and 2001,
respectively, and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine was approved in 2003. Although a combination capsule
containing memantine and donepezil was approved in 2014, no new
novel AD therapies have been approved by the FDA since memantine
in 2003, and tacrine is no longer marketed. Aducanumab’s accelerated
approval by the FDA marks the first AD treatment to address a defining
pathology of the disease. Given the projected growth of the AD popu-

RESEARCH IN CONTEXT
∙ Since 1995, private funding for clinical stage AD research
has been US $42.5 billion
∙ The cost of AD drug development is high, and failures are
common
∙ Better means to lower research cost burden and share
risks are needed

lation and the tremendous personal, social, and economic costs of the
disease, the demand for more new and effective treatments is more
important than ever.

agents included multiple potential mechanisms of action in AD (eg,

1.3

Purpose of this analysis

amyloid-related, tau, cholinergic system, neurotransmitters, inflammation, cholesterol, unknown, or other as categorized on alzforum.org). A

The purpose of our investigation was to quantify the financial aspects

known caveat of collecting such data from multiple secondary sources

of AD drug development in the private sector and the cost of bring-

is that they may not be exhaustive, and thus there is a potential that

ing new treatments to patients. To that end, we examined the invest-

some trials were excluded. Second, based on this initial list of 243

ment in private AD research over the past 26 years in terms of research

agents (and using individual agent names as search terms), records

and development (R&D) costs, patient participation, and drug develop-

specific to 1132 trials were found using ClinicalTrials.gov and AdisIn-

ment program discontinuations. We propose ways to reduce R&D costs

sight (Springer Nature); we deferred to ClinicalTrials.gov as the pri-

while maintaining the rigorous search for more effective therapies.

mary source (Figure 1). Third, of these trial records, eight agents (medical foods or medical devices; n = 35 trial records) were removed, and
a total of 1097 trial records were manually confirmed for data anal-

2

METHODS

ysis. Fourth, internet searches for press releases and other company
information regarding agents, their clinical trials, program termina-

2.1

Data collection

tions, and asset discontinuations were used to complement the initial
search methodology. For each clinical development program identified,

To estimate private R&D funding in AD, we considered and con-

we recorded the trial phase as of June 21, 2021, or the phase in which a

solidated information from multiple sources and databases: Clini-

trial had a negative outcome showing no drug-placebo difference; the

calTrials.gov, AdisInsight, PubMed, Alzforum, and GlobalData. First,

number of trial participants; and the cumulative costs of the collective

agents that had reached clinical stage development in AD (as of June

R&D for each candidate AD treatment based on the model described

11, 2021) were identified using alzforum.org. This initial list of 243

below.

3
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F I G U R E 1 PRISMA flowchart of trial records included in the estimates. a Initial list of agents derived from those listed on Alzforum in June of
2021. These agents included those with potential mechanisms in key areas of study in AD: amyloid pathway, tau pathway, inflammation, and
neurotransmitters. Agents with mechanisms that were not pursued by larger organizations or where dollar investment may be insignificant were
excluded

2.2

Data development

The number of trial participants was calculated from information listed
on ClinicalTrials.gov for relevant trials. Where possible, we defaulted

3
3.1
costs

RESULTS
AD clinical trial failures and cumulative R&D

to intent-to-treat population estimates. In some cases, numbers of trial
participants were found in published articles through PubMed or Alz-

Since 1995, total private funding of AD R&D reached an esti-

forum.org therapeutic databases (using filters for "Alzheimer’s disease"

mated $42.5 billion. These expenditures have been devoted nearly

and phases 1, 1/2, 2, 2/3, 3, and 4). Search results were culled and

exclusively to agents that have failed to reach approval (Figure 2,

inspected by two independent reviewers.

Table 1). Figure 1 shows the cumulative total of the private expen-

The overall cost of a drug development program was estimated

ditures since 1995. Of 235 agents analyzed, 112 remain in active

based on the highest phase of clinical development (phase 1, 2, or 3)

clinical development, six have reached commercialization, and 117

that was achieved for each investigational agent and based on data

have had negative outcomes in various stages of clinical develop-

extracted from Scott et al. (2014).7 Cumulative R&D expenditures

ment (36 as late-stage failures; Table 1), equating to a 95% failure

associated with each stage were assigned per drug in development:

rate.

$79 million for phase 1, $141 million for phase 2, and $462 million
for phase 3 or phase 4; these estimates were adjusted for inflation to
reflect 2021 US dollars using an inflation calculator9 based on the lat-

3.2

Patient participation

est data from the US Bureau of Labor and Statistics’ Consumer Price
Index.10 For example, the total cost for a clinical development program

Clinical trials can proceed only with participants who form a critical

in phase 3 was estimated as $462 million regardless of the number of

alliance with researchers and allow themselves to be assigned to a

phase 1-3 trials that have been conducted for that particular agent.

placebo or an active agent with unknown efficacy and safety. Time,

Failure rate was calculated as discontinuations/(discontinuations +

effort, and commitment are required of both the participant and the

approvals). This analysis did not consider the cost of non-clinical stud-

care partner, who often serves as a surrogate reporter of trial informa-

ies or the costs incurred by patients and their families (eg, transporta-

tion. In the 1097 AD drug trials conducted since 1995, 183,679 partic-

tion, lost days of work, etc).

ipants have entered or are currently enrolled.

4
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F I G U R E 2 The collective cost of AD drug development since 1995. The graph illustrates the year-over-year cumulative estimated cost of drug
development for agents in phases 1, 2, 3, and 4. R&D, research and development

3.3

Distribution of AD R&D efforts

loss of exclusivity for the tablet or capsule formulations, donepezil,
rivastigmine, and galantamine had a combined global sales of ≈$5

Clinical development of AD treatments has been aimed at a vari-

billion.2 By 2016, consumer expenditures on these agents had fallen to

ety of disease targets, mostly synaptic dysfunction and the amyloid-

$1.4 billion due to the entry of generics.2 Approximately half of all US

β protein (Figure 3), with many advancing to phase 2 and 3 devel-

patients diagnosed with AD receive treatment with ChEIs, indicating

opment. Figure 4 shows the highest clinical trial phases reached for

that millions of patients with AD have been treated with these agents

drugs in development programs, both discontinued and ongoing, since

since they were assigned generic status.11

1995.
The highest costs ($24.1 billion) of R&D have been incurred during
phase 3 development (Figure 5). The combined cost of phases 2 and 3

4

DISCUSSION

clinical development since 1995 (≈$33.7 billion) reflects the tremendous potential savings had mechanisms to identify lack of efficacy at

4.1

The rising costs of AD

early-stage development been available.
AD currently costs the US nearly $612 billion/year: $355 billion in
direct costs (including $76 billion in out-of-pocket spending) and $257

3.4

ChEIs inform the innovation cycle

billion in indirect costs.12 For the individual patient with AD, lifetime costs can exceed $500,000 when diagnosed at age 75 years,

The development of ChEIs for AD sparked a cycle of innovation in AD

with patients/families shouldering ≈86% of the net costs from infor-

treatments, leading to advances in our understanding of the disease

mal caregiving and out-of-pocket payments.13 The complete burden of

process and the many potential therapeutic pathways, including

this disease is exceedingly difficult to determine, but an effective ther-

those that might modify the disease course. Based on our assessment

apy to prevent, delay, or alter its course has the potential to greatly

methodology, the estimated phase 3 development cost for donepezil,

reduce both measurable and immeasurable societal and personal

rivastigmine, and galantamine was $1.4 billion ($454 million each

costs.

for having reached phase 3 development); however, this is likely an
underestimation due to the large number of phase 3 clinical trials
conducted for these drugs. Collectively, 29 phase 3 clinical trials have

4.2

The cost of progress

been conducted for these three drugs alone—representing 14.8%
of all phase 3 AD trials conducted since 1995. The oral (capsule or

According to a 2014 analysis, the total estimated cost to develop

tablet) formulations of the ChEIs each had market exclusivity for

a treatment specifically for AD from the non-clinical stage to FDA

approximately a decade from the launch date. In the 12 months before

approval was $5.7 billion and took >13 years to accomplish.7 The

5
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TA B L E 1

Cumulative R&D statistics, 1995 to 2021

Approved, n

Late-stage
discontinuation, n

Discontinued, n

Failure rate, %

R&D, cost,
$ millions

Year

Patients, n

1995

13,870

1

1

1

50

1800

1996

19,642

2

2

2

50

3000

1997

30,790

2

3

2

60

4000

1998

34,558

2

4

2

67

5800

1999

36,519

2

6

3

75

6400

2000

39,591

3

11

7

79

6800

2001

43,709

4

13

8

76

8200

2002

44,919

4

15

8

79

9100

2003

51,116

5

15

8

75

11,000

2004

56,137

5

17

9

77

12,100

2005

64,801

5

21

12

81

13,400

2006

71,402

5

24

12

83

14,600

2007

81,832

5

30

15

86

16,200

2008

92,687

5

34

18

87

18,300

2009

104,904

5

42

22

89

20,300

2010

112,915

5

47

25

90

21,900

2011

117,651

5

50

25

91

23,400

2012

126,164

5

57

27

92

24,600

2013

137,698

5

65

28

93

27,300

2014

144,984

5

71

28

93

30,000

2015

159,520

5

81

28

94

34,100

2016

167,277

5

91

29

95

36,000

2017

169,472

5

95

29

95

37,400

2018

172,068

5

105

32

95

39,000

2019

173,775

5

113

34

96

40,400

2020

176,964

5

114

36

96

41,700

2021

183,679

6

117

36

95

42,500

Numbers represent cumulative totals of pharmaceutical research and development (R&D) out-of-pocket costs for agents in phase 1, 2, 3, or 4 development
between 1995 and 2021.9,11 For each calendar year, the status of each clinical development program (phase of development or whether the program resulted
in an approved agent or discontinuation) was recorded in an Excel spreadsheet. A phase 3 program discontinuation was counted as a late-stage discontinuation. Failure rate was calculated as discontinuations/(discontinuations + approvals).
Additional R&D out-of-pocket costs were added to the cumulative total only when an agent reached the next phase in clinical development. Year-over-year
R&D cost for each agent was also recorded in the Excel spreadsheet. The number of patients involved in each development program was synthesized based on
information from ClinicalTrials.gov, AdisInsight database, primary publications, and Alzforum database. Summary statistics across 235 agents were calculated
for each year, and year-over-year cumulative data is presented here.

methodology used in our study differs in that we focused only on the

to phase 4 drug development over the past 26 years. The impact of

R&D costs for phases 1 through 4 of clinical development.

aducanumab on care costs is not yet known.

The current trajectory of costs for AD patient care is unsustainable and puts the costs of treatment R&D in perspective. Projected
costs in the US alone are expected to surpass $1 trillion annually by

4.3

NIH funding has an important impact

2050.14 According to a 2015 Alzheimer’s Association report, had an
AD treatment breakthrough that delayed the onset of AD by 5 years

In addition to the private costs systematically captured in this review, a

been available in 2015, the cumulative reduction in total costs to all

large portion of AD R&D is supported by public funding. It is more chal-

payers would have been $447 billion by 2050.14 Savings in 2020 alone

lenging to comprehensively capture these costs across the globe. Since

($50 billion) could have financed the total investment in AD phase 1

2008, the National Institutes of Health (NIH) has funded ≈$13 billion

6

CUMMINGS ET AL .

F I G U R E 3 Agents in clinical development by key disease targets. The chart summarizes the highest development phase for each agent (n) in
clinical development for Alzheimer’s disease, categorized by the key disease targets as defined by the Common Alzheimer’s Disease and Related
Dementias Ontology16

F I G U R E 4 Highest clinical trial phase reached for agents in clinical development for Alzheimer’s disease (AD). The chart summarizes agents (n)
in clinical development for AD from 1995 to 2021, categorized by the highest clinical trial phase reached for discontinued (red) and ongoing
(green) agents

7
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advances. Our analyses identified two important areas where cost savings can be realized. First, the use of biomarkers—especially bloodbased markers—may substantially reduce the cost of participant identification and enrollment.18 Second, identifying failures earlier in the
development process could reduce the high costs of unproductive
phase 3 trials, decreasing overall R&D expenditures and therefore lowering direct medical costs for both patients and payers.

4.5

Continuing investments in AD drug R&D

Although public funding has complemented private R&D and encouraged public-private research relationships, the financial responsibility
F I G U R E 5 Drug development cost by clinical trial phase. The
chart illustrates the estimated cost of AD drug development from
1995 to 2021 for agents in phases 1, 2, and 3

for drug development has fallen largely on the pharmaceutical industry. In many therapeutic areas, including AD, the rising costs of drug
development are neither sustainable nor desirable and may impede
innovation. The financial risk of pursuing candidate AD drugs is exceptionally high, and comparatively few companies and academic labora-

in AD research distributed through grants awarded by various adminis-

tories have accepted the challenge of researching AD and other NDDs.

tering institutes or centers. According to the International Alzheimer’s

More diversified sources of funding and collaboration between govern-

and Related Dementias Research Portfolio (IADRP) database,15,16

ment, academia, and private and publicly traded companies, along with

an additional $3 billion outside of NIH funding was invested in AD

strategic policy measures aimed at supporting innovation,19 could lead

research between 2008 and 2020. Public funding devoted to basic

to numerous effective and affordable therapies. Although government

research is critical to developing disease understanding, identifying

funding for AD research has increased sixfold over the past 10 years,

targets for therapy, nominating therapeutic classes and agents, and dis-

AD ranks 23rd in terms of NIH investment despite its position as one

covering new biomarkers.

of the top 10 causes of death among Americans.20 To bridge the gap
between direct government budget allowances for AD research and
the need for more research investment, expanded policies rewarding

4.4

Changing the AD trajectory

companies and investors who risk NDD R&D could incentivize research
in notoriously difficult areas of innovation.

Although AD research has led to only six approved symptomatic treatments, the benefits of successful development of these drugs extend
beyond providing new therapies to patients. Over the past 26 years,

4.6

ChEIs and the innovation cycle

the field as a whole has gained understanding of the complex biology
of AD, identified numerous potential targets for future drug develop-

Investment in the development of ChEIs for AD is greater than any

ment, developed new and informative biomarkers, extended the range

other single-candidate AD agent, and their use is anticipated to con-

of AD trial populations to include preclinical and prodromal states of

tinue into the foreseeable future as part of a treatment regimen with

AD, improved trial designs and measures, and enhanced the quality of

disease-modifying and other types of therapies.21 The recognition of

trial conduct.

the cholinergic pathway as a target for development of ChEIs led

While R&D costs have increased in every therapeutic area, much of

researchers to examine additional pathways and potential therapeu-

the expense of developing AD therapies lies in the difficulty of quickly

tic targets and several ChEIs with improved safety and tolerability pro-

and accurately identifying clinical trial participants. The field needs

files, and improved formulations were developed and approved soon

new targets with greater therapeutic potential, improved animal mod-

after the vanguard agent. Following the exhaustion of market exclusiv-

els, and reliable surrogate biomarkers that can signal efficacy or lack

ity and the availability of less-expensive generic alternatives, the cost

of effect earlier in clinical development. There is continued interest

of these symptomatic treatments has decreased substantially.22 This

in the amyloid-β protein as a drug development target, and one drug

illustrates the overall cycle of innovation in drug development whereby

addressing this target has been approved; analysis of the distribution

innovation is rewarded by market exclusivity for a period of time, prior

of R&D investment suggests that there is progressive emphasis on non-

to the entry of lower-priced generics, providing capital for the next

amyloid targets.17

wave of innovation and thereby extending benefits to patients beyond

Approval of a disease-modifying therapy may begin to change

the period of exclusivity. In this manner, biopharmaceutical companies

the trajectory of the expected AD burden by 2050.14 The high cost

reinvest profits in R&D to discover and advance the next generation of

of drug development limits drug development and delays treatment

novel medications.23

8
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4.7

Stimulating innovation

of this information exists. Additionally, R&D costs per company are not
reported in a manner discrete enough to attribute to a single agent or

The success of the first disease-modifying therapy in AD has the

trial, thereby making a list specific to AD or exhaustive of the agents in

potential to reinvigorate the AD R&D pipeline, empower cycles of

development challenging.

additional innovation, and generate momentum toward future successes despite a long history of failures in AD drug development.
The few successes in new drug approvals in the US for AD since

4.9

Where do we go from here?

2003 suggest that additional means of attracting innovators are
needed. The exit of many biopharmaceutical companies from CNS

The burden of AD to society is rising at an alarming rate, and innova-

drug development indicates that current incentives are insufficient to

tive ways to slow this trend and develop new therapies are required.

keep companies engaged and accept the development risks. NDD drug

By incentivizing investment, redirecting these investments to new and

development might be made more attractive with incentives pioneered

innovative ways to advance drug development, and diversifying R&D

in orphan drug development, including significant tax credits for qual-

funding across public, private, and academic entities, we may acceler-

ified clinical testing, waiver of the marketing application fee required

ate development of treatments that prevent, delay, or alter the disease

of sponsors at the time of submission to the FDA, and extended mar-

course.

keting exclusivity.24,25 These incentives have attracted innovation and
led to the development of efficacious drugs for rare diseases.26 Similar
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REFERENCES
1. Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug
discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology. 2017;120:11-19.
2. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drugdevelopment pipeline: few candidates, frequent failures. Alzheimer’s
Res Ther. 2014;6:37.

9

CUMMINGS ET AL .

3. Berger JR, Choi D, Kaminski HJ, et al. Importance and hurdles to drug
discovery for neurological disease. Ann Neurol. 2013;74:441-446.
4. Choi DW, Armitage R, Brady LS, et al. Medicines for the mind: policybased “pull” incentives for creating breakthrough CNS drugs. Neuron.
2014;84:554-563.
5. Rinaldi A. Setbacks and promises for drugs against Alzheimer’s
disease: as pharmaceutical companies are retreating from drug
development for Alzheimer’s, new approaches are being tested in
academia and biotech companies. EMBO Rep. 2018;19:e46714.
6. Yokley BH, Hartman M, Slusher BS. Role of academic drug discovery in
the quest for new CNS therapeutics. ACS Chem Neurosci. 2017;8:429431.
7. Scott TJ, O’Connor AC, Link AN, Beaulieu TJ. Economic analysis of
opportunities to accelerate Alzheimer’s disease research and development. Ann N Y Acad Sci. 2014;1313:17-34.
8. Malzbender K, Lavin-Mena L & Hughes L et al. Key barriers to clinical
trials for Alzheimer’s Disease. Leonard D Schaaeffer Center for Health
Policy & Economics. 2020.
9. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s
disease drug development pipeline: 2019. Alzheimers Dement (N Y).
2019;5:272-293.
10. US Bureau of Labor Statistics. Consumer Price Index. https://www.bls.
gov/cpi. Accessed June 25, 2021.
11. Bent-Ennakhil N, Coste F, Xie L, et al. A real-world analysis of
treatment patterns for cholinesterase inhibitors and memantine
among newly-diagnosed Alzheimer’s disease patients. Neurol Ther.
2017;6:131-144.
12. Alzheimer’s disease facts and figures. Alzheimer’s Dement.
2021;17:327-406.
13. Jutkowitz E, Kane RL, Gaugler JE, et al. Societal and family lifetime cost
of dementia: implications for policy. J Am Geriatr Soc. 2017;65:21692175.
14. Alzheimer’s Association. Changing the Trajectory of Alzheimer’s Disease:
How a Treatment by 2025 Saves Lives and Dollars. https://www.alz.org/
media/documents/changing-the-trajectory-r.pdf. Accessed June 25,
2021.
15. Liggins C, Snyder HM, Silverberg N, et al. International Alzheimer’s
Disease Research Portfolio (IADRP) aims to capture global
Alzheimer’s disease research funding. Alzheimer’s Dement.
2014;10:405-408.
16. International Alzheimer’s and Related Dementia Research Portfolio. Common Alzheimer’s and Related Dementias Research Ontology
(CADRO). 2021.
17. Cummings JL, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2020. Alzheimer’s Dement (N Y). 2020;6(1):16.
18. Mattke S, Cho SK, Bittner T, et al. Blood-based biomarkers for
Alzheimer’s pathology and the diagnostic process for a disease-

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.
29.

modifying treatment: projecting the impact on the cost and wait times.
Alzheimer’s Dement (Amst). 2020;12:e12081.
Goldman DP, Fillit H, Neumann P. Accelerating Alzheimer’s disease
drug innovations from the research pipeline to patients. Alzheimer’s
Dement. 2018;14:833-836.
National Institutes of Health Estimates of funding for various research,
condition, and disease categories (RCDC). https://report.nih.gov/
funding/categorical-spending#/. Accessed June 25, 2021
Cummings JL, Tong G, Ballard C. Treatment combinations for
Alzheimer’s disease: current and future pharmacotherapy options. J
Alzheimer’s Dis. 2019;67:779-794.
Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and
late-stage drug development for Alzheimer’s disease: an appraisal
from 1984 to 2014. J Intern Med. 2014;275:251-283.
Moreno SG, Epstein D. The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework. J
Mark Access Health Policy. 2019;7:1583536.
Le TT. Incentivizing orphan product development: United States food
and drug administration orphan incentive programs. Adv Exp Med Biol.
2017;1031:183-196.
Mueller CM, Rao GR, Miller Needleman KI. Precision medicines’
impact on orphan drug designation. Clin Transl Sci. 2019;12:633640.
Burke KA, Freeman SN, Imoisili MA, Cote TR. The impact of the
Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review. Clin Pharmacol
Ther. 2010;88:449-453.
Khachaturian ZS, Khachaturian AS. The paradox of research on
dementia-Alzheimer’s disease. J Prev Alzheimers Dis. 2016;3:189191.
Lo AW, Ho C, Cummings J, Kosik KS. Parallel discovery of Alzheimer’s
therapeutics. Sci Transl Med. 2014;6(241):241cm5
Goldman M, Compton C, Mittleman BB. Public-private partnerships as
driving forces in the quest for innovative medicines. Clin Transl Med.
2013;2:2.

How to cite this article: Cummings JL, Goldman DP,
Simmons-Stern NR, Ponton E. The costs of developing
treatments for Alzheimer’s disease: A retrospective
exploration. Alzheimer’s Dement. 2021;1-9.
https://doi.org/10.1002/alz.12450

